IL2

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
Friday, April 5, 2024
CD4, CD8, AMP, Development, Antigen, Immunotherapy, Colorectal cancer, Memory, Patient, Lung, GM-CSF, Biomarker, DNA, Epitope, Cancer, Granzyme B, BRAF, Lymph, IL2, Circulating tumor DNA, Phenotype, Neoplasm, Research and development, Immunization, Therapy, Vaccination, CRC, V600E, Immune system, Melanoma, Granzyme, Phase 1, Amphetamine, Nature Medicine, Annual general meeting, Vaccine

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

Obsidian Therapeutics Presents Positive 25-Week Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Toxicity, NSCLC, TIL, Disease, Patient, University, MD Anderson Cancer Center, AACR, IL2, ICI, Therapy, Safety, Poster, PFS, Capillary leak syndrome, Cytokine release syndrome, Pharmaceutical industry

, professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center and principal investigator of the study.

Key Points: 
  • , professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center and principal investigator of the study.
  • The single-center study ( NCT05470283 ) is evaluating the safety, tolerability, dosing, and efficacy of OBX-115 in patients with ICI-resistant metastatic melanoma.
  • All 6 patients had disease that was primary-resistant to anti–PD-1 therapy, with a median of 2.5 (range, 1–5) lines of prior therapy.
  • In addition to the first-in-human study, Obsidian is actively enrolling patients with metastatic melanoma and NSCLC at multiple sites in its ongoing Phase 1/2 multicenter study.

Bonum Therapeutics to Present Poster on Lead Program at AACR 2024

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health Technology, Pharmaceutical, Health, Therapy, Acquisition, Engineering, IL-12, Doctor of Philosophy, Roche, Safety, AACR, Cell, IL2, Cytokine, Patient, Poster, Biology, TGF, Pharmaceutical industry

Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.

Key Points: 
  • Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.
  • The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic.
  • John Mulligan, PhD, Bonum Therapeutics’ CEO, commented, “We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”
    The poster will be available on the Bonum website on the day of the presentation.
  • The merits of the platform were validated by the Roche acquisition of Good Therapeutics and its PD-1-regulated IL-2 program in September 2022.

Qlik Achieves StateRAMP Authorization for Qlik Cloud Government, its AI-Powered Cloud Analytics Platform That Helps State and Local Agencies Make Data-Driven Decisions

Retrieved on: 
Thursday, November 16, 2023
Cloud, Catalog, Workforce, Intuition, State, Public sector, National Association, Arizona Department, FedRAMP, IL2, Qlik, Administration, DOD, AWS, Amazon Web Services, Renewable energy

PHILADELPHIA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Qlik ® announced today that Qlik Cloud ® Government has achieved StateRAMP Moderate Authorization.

Key Points: 
  • PHILADELPHIA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Qlik ® announced today that Qlik Cloud ® Government has achieved StateRAMP Moderate Authorization.
  • Achieving StateRAMP authorization enables all United States state and local governments and public educational institutions to confidently leverage Qlik Cloud to further their data transformation through modern cloud analytics.
  • This authorization also enables them to leverage advanced AI while meeting the rigorous security standards set forth by StateRAMP.
  • Qlik Cloud Government serves as a standard for public sector cloud analytics, empowering organization-wide data-driven decisions through a cloud modern platform.

Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Therapy, ICI, RECIST, University, National Resilience Institute, Disease, Patient, IL15, Monroe Dunaway Anderson, Neoplasm, DCR, ORR, Melanoma, IL2, CTMC, MD Anderson Cancer Center, TIL, Pharmaceutical industry, Obsidian

OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.

Key Points: 
  • OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.
  • , professor of Melanoma Medical Oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center.
  • “The OBX-115 data show its potential to be a meaningful advancement in the treatment of metastatic melanoma and TIL cell therapy,” said Parameswaran Hari, M.D., M.S., Chief Development Officer of Obsidian Therapeutics.
  • “These positive results underscore the potential for OBX-115 TIL cell therapy to offer patients with metastatic melanoma a differentiated TIL therapy without the need for IL2,” said Madan Jagasia, M.D., M.S., CEO of Obsidian Therapeutics.

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Retrieved on: 
Monday, October 16, 2023
BSE, ANZ, CSO, MD, HR, Toxicity, L19, Sun Pharma, Melanoma, BIT, NSE, Phase, Reuters, Patient, Neoadjuvant therapy, IL2, RFS, Skin, Medical imaging, Pharmaceutical industry, Jaden Philogene

The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm).

Key Points: 
  • The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm).
  • According to the protocol, the primary endpoint of the study was the Recurrence-Free Survival (RFS) assessed per Blinded Independent Central Review (BICR) for patients treated with Nidlegy™, compared to the control arm.
  • At median follow-up of 27.6 months in both groups, the study met its primary endpoint with a statistically significant and clinically meaningful improvement in RFS of the treatment arm compared to the control arm.
  • Prof. Dario Neri, co-founder, CEO and CSO of Philogen, commented: "We are extremely pleased to announce positive topline data emerging from our PIVOTAL program in locally advanced resectable melanoma.

DTech Apps Announces Latest Release of the Award Winning DocIntegrator Suite Providing Forms Automation for Federal Defense and Civilian Clients in the ServiceNow Store

Retrieved on: 
Tuesday, October 3, 2023
Data Management, Technology, Professional Services, Security, Apps, Applications, Software, Government Technology, Other Defense, Networks, Defense, Fintech, Cloud, SharePoint, Workflow, Microsoft, Confidentiality, IL4, Organization, FISMA, ServiceNow, Federation, JWICS, Doctor of Technology, IL2, PII, Automation, Mobile phone, Online shopping

DTech Apps, the leader in secure enterprise productivity apps for ServiceNow, announced the latest product updates to the award-winning DocIntegrator Suite of solutions.

Key Points: 
  • DTech Apps, the leader in secure enterprise productivity apps for ServiceNow, announced the latest product updates to the award-winning DocIntegrator Suite of solutions.
  • The DocIntegrator Suite Fall Update boasts a range of enhancements, primarily focusing on the improvement of DocGenerator, DTech Apps' forms automation product for ServiceNow, and DocIntegrator, their Microsoft SharePoint integration product for ServiceNow.
  • Both of these exceptional products are exclusively available through the ServiceNow Store and are certified to be compatible with GCC Cloud (IL2, IL4), JWICS, FISMA, and FedRamp High environments.
  • DTech Apps is trusted and certified by the US federal government to provide solutions that require constant uptime and the highest level of security.

Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer

Retrieved on: 
Tuesday, August 8, 2023
Lymphoma, TST, CD25, Nature Cancer, Pharmaceutical innovations, Food and Drug Administration, Cancer, Immunity, Toxicity, Antibody, HKEX, Patient, Interleukin 2, GZMB, Ophthalmology, Immune system, Neoplasm, Cytokine, PD-1, IL2, TeST TST-13 Junior, Food, Safety, Vaccine, Pharmaceutical industry, Palladium, Regulatory T cell

and SUZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the preclinical results of IBI363 were published in Nature Cancer (IF=22.7).

Key Points: 
  • and SUZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the preclinical results of IBI363 were published in Nature Cancer (IF=22.7).
  • Interleukin 2 (Interleukin-2, IL-2) is the first cytokine to be discovered and identified as playing a pivotal role in T-cell growth and expansion.
  • In contrast, "not-α" IL-2 is prone to expand CD25 negative bystander T cells, and this limits its anti-tumor efficacy.
  • The corresponding author, Dr. Kaijie He of Innovent Biologics stated, "We are very pleased that the results of this study are published and highlighted in the current issue of Nature Cancer.

Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

Retrieved on: 
Wednesday, July 26, 2023
KRYS, US Foods, DNA, Human, Research and development, Krystal, Immunology, Drug discovery, Clinical trial, Skin, National Cancer Institute, Suma, Research, Associate, Lung, IL12, ET, MD, Patient, Lymph, Division, Blood, Webcast, UPMC, Cytokine, FDA, IL2, Safety, Gene, Tumor microenvironment, IND, Food, Pharmaceutical industry, Vaccine, Medicine

The Company will host an investor conference call and webcast, Thursday, July 27, 2023, at 8:00 am ET, to discuss the KB707 program.

Key Points: 
  • The Company will host an investor conference call and webcast, Thursday, July 27, 2023, at 8:00 am ET, to discuss the KB707 program.
  • The presentation for the investor conference call is attached to the Company’s Form 8-K .
  • Two formulations of KB707 are in development, a solution formulation for transcutaneous injection and an inhaled (nebulized) formulation for lung delivery.
  • “We believe KB707 is a unique and highly differentiated drug candidate with the potential to unlock the capabilities of cytokine-based immunotherapy,” said Suma Krishnan, President of Research & Development at Krystal Biotech.

Autolus Therapeutics announces publication in Cancer Immunology Research

Retrieved on: 
Tuesday, June 27, 2023
Antigen, IL18, Face, Survival, CAR, GM, Architecture, IL2, Therapy, IL7, Disease, Vaccine

LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Cancer Immunology Research1 entitled: ‘Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors.’

Key Points: 
  • LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Cancer Immunology Research1 entitled: ‘Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors.’
    For CAR T cells to be effective, they must engraft in the patient, expand to sufficient numbers and persist at the site of disease.
  • Often this can involve intervals in the absence of cognate antigen, for instance during trafficking, or in the face of a hostile tumor microenvironment.
  • T cells in a physiological immune response are supported by a network of immune cells which provide cytokine signals to stimulate proliferation and survival.
  • “Achieving sufficient CAR T cell expansion and persistence can be difficult when targeting solid cancer antigens,” said Dr Martin Pule, Chief Scientific Officer and Founder of Autolus.